Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed Compounded "semaglutide" is not FDA approved semaglutide.com Hims & Hers stock rises 14% as FDA schedules peptide compounding review FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide